ArticleScientific data2026
Longitudinal Proteomics Analysis of Cerebrospinal Fluid in Survivors of Childhood Acute Lymphoblastic Leukemia.
Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mass spectrometry-based proteomic profiling of cerebrospinal fluid (CSF) in large patient cohorts, particularly among childhood cancer survivors, remains scarce, limiting opportunities for benchmarking, method development, and validation. Here, we present a longitudinal CSF proteomics dataset from survivors of childhood acute lymphoblastic leukemia (ALL). Samples were collected from 178 patients enrolled in the TOTXVI therapeutic protocol at two timepoints: diagnosis (pre-treatment) and during the consolidation phase of chemotherapy (totaling 356 samples). CSF proteomes were profiled using tandem-mass-tag (TMT) labeling coupled with extensive fractionation and high-resolution liquid chromatography-tandem mass spectrometry (LC/LC-MS/MS). The dataset includes quantitative profiles for more than 3,000 confidently identified unique proteins. This dataset enables the investigation of chemotherapy-induced alterations in the CSF proteome and provides a valuable resource for studying the molecular mechanisms of neurotoxicity, identifying biomarkers of adverse late effects, and guiding the development of neuroprotective strategies in childhood cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.